From Journal of the American Herbalist Guild

A group  of Indian  and  German  scientists  conducted  an open,  non-randomized pilot study to  test the hypothesis that  Boswellia  might  be  beneficial  for  the  treatment  of ulcerative   colitis.   For   the  study,   34   patients   (18   with
grade 11 and  16 with grade 3 colitis) were given 350 mg of Boswellia resin three times a day, and 8 patients (5 with
grade 11  and 3 with grade 3 colitis)  were given the drug sulfasalazine, 1 g three  times   a   day.   The  authors
commented that the cost of the drug was responsible for the  small  control  group.  Symptoms  such  as  abdominal
palms,  loose stools,  mucus,  and  blood  Improved in  both groups,  with  results  for  the  control  sulfasalazine  group slightly better than the  Boswellia group.  

Sigmoidoscopic examination  for  the  grading  of  the  disease  and  rectal biopsies  both  showed  substantial  improvements  in  the two   treatment   groups,   and   there   was   no   statistically
significant difference between the groups. About 80% of the patients receiving Boswellia went into remission. The authors   concluded   that   although    they   could    not statistically   confirm   the   superiority   of  Boswellia   over sulfasalazine, the data suggest that it is at least not inferior. 
Twenty   patients   with   chronic   colitis    received Boswellia  gum  resin  (900  mg  per  day  for  6  weeks)  and another  10  patients were given sulfasalazine  (3  g per day for  6  weeks)  in  an  open-label  trial.  Out  of 20  patients treated  with  Boswellia,   14  went   into   remission   (70% compared to 40% for sulfasalazine).

Journal of the American Herbalist Guild Vol 6 issue 1

Read the GENESIS Disclaimer.